Prof. Guangyuan Hu 胡广原
Chief Physician, Professor
Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan
Public profile Compiled from public listings and PubMed. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionClinical focus: Radiation therapy, chemotherapy, and molecular targeted therapy for malignant tumors. Specializes in radiation therapy for head and neck and chest malignancies.
Dr. Hu holds a medical doctorate and is a professor and chief physician. Graduating from Tongji Medical University in 1996, Dr. Hu has over 20 years of experience in clinical diagnosis and treatment of malignant tumors. Dr. Hu serves as Director of the Head and Neck Tumor Department at Tongji Hospital. Research includes over 30 published papers and leadership in multiple provincial and national projects.
Professional roles
- Member, Chinese Medical Association
- Vice Chair, Tumor Nutrition and Metabolism Professional Committee, Hubei Anti-Cancer Association
- Standing Committee Member, Nasopharyngeal Cancer Professional Committee, Hubei Anti-Cancer Association
- Standing Committee Member, Radiosurgery Professional Committee, Radiation Oncology Branch, Chinese Medical Doctor Association
Name order: in Chinese the family name comes first (Hu Guangyuan). Papers usually list the name as Guangyuan Hu or Hu G.
Selected publications
94 papers on PubMed matched by name and affiliation; 24 as first or senior author since 2016. Most recent first- or senior-author papers:
- Precis Radiat Oncol, 2026 (senior author): Effects of proton therapy on the tumor immune system and clinical implications: A review. PubMed 42632996
- Genes (Basel), 2026 (senior author): CALB2 Expression Is Associated with Tumor Progression and Prognosis in Colorectal Adenocarcinoma. PubMed 42194967
- Clin Cancer Res, 2026 (senior author): A Phase II Trial of Neoadjuvant Albumin-Bound Paclitaxel plus Carboplatin Combined with Tislelizumab in Locally Advanced HNSCC: Efficacy and Biomarker Exploration. PubMed 41252569
- Epigenetics, 2025 (senior author): Association of systemic immune-inflammation index (SII) with epigenetic age acceleration in adults: insights from NHANES. PubMed 40758856
- Biomedicines, 2025 (senior author): Lipid Metabolism Reprogramming in Cancer: Insights into Tumor Cells and Immune Cells Within the Tumor Microenvironment. PubMed 40868150
- Curr Oncol, 2025 (senior author): Depression and Anxiety After Radiation-Induced Brain Injury: A Review of Current Research Progress. PubMed 40862788
- Biomedicines, 2025 (senior author): Urolithin A in Central Nervous System Disorders: Therapeutic Applications and Challenges. PubMed 40722629
- PeerJ, 2025 (senior author): The prognostic model of low-grade glioma based on m6A-associated immune genes and functional study of FBXO4 in the tumor microenvironment. PubMed 40130175
See the full PubMed search. Automatic matching can miss papers or include a namesake at the same hospital.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and write a treatment plan with a cost estimate.
Get a specialist opinion